Piper Sandler has increased its price target for Incyte (INCY) to $110, maintaining an Overweight rating. This update reflects a 7.84% hike from the previous target of $102. Other analysts have also recently adjusted their targets for Incyte, with the average one-year price target from 22 analysts being $104.31, suggesting a slight downside from the current price, while the consensus brokerage recommendation indicates an “Outperform” status.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Piper Sandler Raises Incyte (INCY) Price Target to $110 | INCY Stock News
Piper Sandler has increased its price target for Incyte (INCY) to $110, maintaining an Overweight rating. This update reflects a 7.84% hike from the previous target of $102. Other analysts have also recently adjusted their targets for Incyte, with the average one-year price target from 22 analysts being $104.31, suggesting a slight downside from the current price, while the consensus brokerage recommendation indicates an “Outperform” status.